CTOs on the Move

Cetac Technologies

www.cetac.com

 
Cetac Technologies is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cetac.com
  • 14306 Industrial Rd
    Omaha, NE USA 68144
  • Phone: 800.369.2822

Executives

Name Title Contact Details

Similar Companies

OnSomble

OnSomble is the leading online nurse community and role-based professional development company in the world.

Contextual Genomics

Transforming cancer care with data driven medicine

Immunicom

Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.

Hanford Pharmaceuticals

Hanford Pharmaceuticals is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rare Cancer Research Foundation

The Rare Cancer Research Foundation (RCRF) is dedicated to curing rare cancers through strategic investments and innovative collaborations that catalyze effective research and accelerate deployment of promising therapies. While rare cancers accounted for just over 25 percent of all new cancer diagnoses in 2013, they comprised more than 40 percent of all cancer deaths. RCRF`s goal is to develop research infrastructure for each rare cancer.